Cite
Preclinical evaluation of the gorilla-derived HAdV-B AdV-lumc007 oncolytic adenovirus 'GoraVir' for the treatment of pancreatic ductal adenocarcinoma.
MLA
Bots, Selas T. F., et al. “Preclinical Evaluation of the Gorilla-Derived HAdV-B AdV-Lumc007 Oncolytic Adenovirus ‘GoraVir’ for the Treatment of Pancreatic Ductal Adenocarcinoma.” Molecular Oncology, vol. 18, no. 5, May 2024, pp. 1245–58. EBSCOhost, https://doi.org/10.1002/1878-0261.13561.
APA
Bots, S. T. F., Harryvan, T. J., Groeneveldt, C., Kinderman, P., Kemp, V., van Montfoort, N., & Hoeben, R. C. (2024). Preclinical evaluation of the gorilla-derived HAdV-B AdV-lumc007 oncolytic adenovirus “GoraVir” for the treatment of pancreatic ductal adenocarcinoma. Molecular Oncology, 18(5), 1245–1258. https://doi.org/10.1002/1878-0261.13561
Chicago
Bots, Selas T F, Tom J Harryvan, Christianne Groeneveldt, Priscilla Kinderman, Vera Kemp, Nadine van Montfoort, and Rob C Hoeben. 2024. “Preclinical Evaluation of the Gorilla-Derived HAdV-B AdV-Lumc007 Oncolytic Adenovirus ‘GoraVir’ for the Treatment of Pancreatic Ductal Adenocarcinoma.” Molecular Oncology 18 (5): 1245–58. doi:10.1002/1878-0261.13561.